Open AccessTransition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
Author(s) -
Burns Stephanie,
Lewis Elena
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4060
Subject(s) - hereditary angioedema , medicine , angioedema , gene , dermatology , pharmacology , genetics , biology
Non‐SERPING1 gene variant hereditary angioedema patients often need to take progesterone, attenuated androgens, and antifibrinolytics to control symptoms. These drugs may need to be tapered to extinction or reduced as lanadelumab‐flyo reaches maximum concentration.